T cell lymphoma
Conditions
Interventions
Transplantation group:allo-HSCT
Control group:Chemotherapy
Sponsors
Peking University People's Hospital
Eligibility
Sex/Gender
All
Age
12 Years to 65 Years
Inclusion criteria
Inclusion criteria: Histology diagnosis(according to the WHO classification) PTCL-NOS (Peripheral T-cell lymphoma, not otherwise specified) AILT (Angioimmunoblastic T-cell lymphoma ALK- ALCL(Anaplastic large cell lymphomas) EATL (Enteropathy-associated T-cell lymphoma HSTL (Hepatosplenic lymphoma) Extranodal NK/T-Cell Lymphoma Age<=65y ECOG<2 Status at HSCT: Responder (CR+PR) patients after induction chemotherapy (CHOEP or CHOP like, 2-3 cycles) PIF/CR or PR: primary induction failure but have a CR/PR to salvage agent
Exclusion criteria
Exclusion criteria: ALK+ ALCL or extranodal NK/T-Cell Lymphoma, nasal Did not achieve CR or PR Organ failure With bulky disease (>= 5cm) at SCT Known HIV positivity ECOG>2 Did not agree to receive allo-HSCT Joint other clinical trial within 28 days
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| engraftment;GVHD;Complete remission;Relapse;Non-relapse mortality;Overall survival; | — |
Countries
China
Contacts
Public ContactMo Xiaodong
Peking University People's Hospital
Outcome results
None listed